Novo Nordisk has long acting Insulin Icodec (weekly injection / LAI287) in phase 2
Not for type 1 diabetes or diabetic ketoacidosis
reports institutional contracts with Amgen, Applied Therapeutics, AstraZeneca, Biomea, Boehringer Ingelheim, Corcept, Eli Lilly, Fractyl, Kailera, Novo Nordisk, Pfizer, Recordati, Rhythm and Servier, and a consultant role at Baim Institute for Clinical Research, Mediflix, Sanofi and Roche
It is particularly active in musculoskeletal and connective tissues
BPC-157 (10mg Vial) Dosage Protocol BPC-157 is a synthetic pentadecapeptide derived from a protein in gastric juice, studied preclinically for tissue repair, recovery from soft-tissue injury, and protection of the gastrointestinal lining